Skip to main content

Table 2 Multivariable hazard ratios for risk of disease recurrence by prognostic factors in centrally confirmed HER2+ placebo patients in TEACH

From: Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

Prognostic factor Hazard ratio (95% CI) P value
Hormone receptor (HR2) status 0.59 (0.42, 0.81) 0.002
  HR+ vs. HR-, 1–5 yrs after diagnosis   
  HR+ vs. HR-, 6–10 yrs after diagnosis 0.97 (0.59, 1.62) 0.92
Age at diagnosis (years)   
  ≥40 vs. <40 0.69 (0.49, 0.96) 0.03
Nodal status   
  Negative vs. positive 0.62 (0.45, 0.87) 0.006
Stage   
  T1 N0 vs. other 0.58 (0.33, 1.0) 0.05
Prior chemotherapy1   
  Anthracycline versus no anthracycline 0.78 (0.38, 1.61) 0.51
  Anthracycline + taxane versus anthracycline alone 0.85 (0.64, 1.14) 0.27
  1. 1Separate models, each including all other prognostic factors, were used to estimate the hazard ratio for anthracycline versus no anthracycline and anthracycline with taxane versus anthracycline alone; 2HR+ = ER+ or PR+; HR- = ER- and PR-. The hazard ratio estimate for each prognostic factor is adjusted for all other factors listed in the table. HER2+, human epidermal growth factor receptor 2 positive; TEACH, Tykerb evaluation after chemotherapy; CI, confidence interval.